Palivizumab
Title: Palivizumab
CAS Registry Number: 188039-54-5
CAS Name: Anti-(respiratory syncytial virus protein F) immunoglobulin G1 (human-mouse monoclonal MEDI-493 g1-chain) disulfide with human-mouse monoclonal MEDI-493 k-chain, dimer
Manufacturers' Codes: MEDI-493
Trademarks: Synagis (MedImmune)
Literature References: Humanized monoclonal antibody directed to a neutralizing epitope on the F glycoprotein of respiratory syncytial virus (RSV). Mol wt ~148 kDa. Consists of ~95% human and ~5% murine antibody sequences. Prepn and neutralizing activity: L. S. Johnson, WO 9605229; idem, US 5824307 (1996, 1998 both to MedImmune); S. Johnson et al., J. Infect. Dis. 176, 1215 (1997). Clinical pharmacokinetics and safety: X. Sáez-Llorens et al., Pediatr. Infect. Dis. J. 17, 787 (1998). Clinical trial in high risk infants: Impact-RSV Study Group, Pediatrics 103, 531 (1998). Review: H. C. Meissner et al., Pediatr. Infect. Dis. J. 18, 223-231 (1999).
Therap-Cat: Antiviral (in prophylaxis of RSV infection).
Keywords: Antiviral; Monoclonal Antibodies.

Others monographs:
MangostinHydramethylnonAntimony ThioglycollamideChlorazanil
FebuprolEthambutolMivazerolNaled
SenecionineBoleko OilBrazilinBensulfuron-methyl
Isovaleryl ChlorideRaubasineSteproninIothalamic Acid
©2016 DrugLead US FDA&EMEA